SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion announced it will present preclinical data for EVX-04, an…

Evaxion A/S · 6-K filed May 12, 2026 at 09:30 ET

At the news

NEUTRALIMPACT 3/10

6-K filed May 12, 2026 at 09:30 ET

Evaxion announced it will present preclinical data for EVX-04, an off-the-shelf therapeutic AML vaccine, at the EHA 2026 Congress in June. The data is preclinical and the company plans to submit a clinical trial application in H2 2026. This is a routine pipeline update with no financial data or near-term catalyst.

  • Evaxion to present functional characterization data for EVX-04 at EHA 2026 Congress on June 13, 2026
  • EVX-04 is an off-the-shelf therapeutic vaccine targeting acute myeloid leukemia (AML)
  • Preclinical data shows EVX-04 prevents tumor growth in preclinical models
  • Company plans to submit a clinical trial application in the second half of 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access